QX027N
Asthma+Atopic Dermatitis
Phase 1Active
Key Facts
About Qyuns Therapeutics
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
View full company profile